Macrocure Hires Dr. Ramesh Tharuvai, Ph.D. as Vice President, Operations
02 Mars 2015 - 12:00PM
Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biopharmaceutical
company focused on developing a novel therapeutic platform to
address chronic and hard-to-heal wounds, today announced that Dr.
Ramesh Tharuvai has joined Macrocure as Vice President, Operations
effective March 2, 2015.
Most recently, Dr. Tharuvai was Vice President,
Manufacturing and Product Supply, at Nuron Biotech, a private,
clinical stage biopharmaceuticals company. Prior to Nuron, Dr.
Tharuvai held senior-level positions at Pfizer and Wyeth within
supply chain and operations. For more than 10 years, he was
responsible for modeling, redesigning, and improving performance in
several global product portfolios as well as establishing the Sales
& Operations Planning process for Wyeth's Vaccine business and
global portfolio. At Pfizer, Dr. Tharuvai had responsibility for
the Specialty Care supply chain, which included 22 brands of
biologics, vaccines, and small molecules.
"Dr. Tharuvai is a seasoned leader with an
established track record of accomplishment in manufacturing, supply
chain management and process optimization," stated Nissim Mashiach,
President and Chief Executive Officer of Macrocure. "Dr. Tharuvai's
experience at small and large companies, including assuring
compliance with FDA and EMA requirements, will be invaluable as
Macrocure expands its manufacturing footprint from clinical stage
production to large scale, commercial operations. His addition is
consistent with our focused strategy to round out our existing
world-class management team. Dr. Tharuvai will lead the
establishment of Macrocure's new manufacturing plant and will be
actively involved in the preparation of our BLA submission,"
concluded Mr. Mashiach.
Dr. Tharuvai holds a B. Tech degree in Chemical
Engineering from the Indian Institute of Technology, and an M.S.
and Ph.D. from Ohio State University. Additionally, he earned a Six
Sigma Black Belt Certification from Villanova University.
About Macrocure Ltd.
Founded in 2008, Macrocure Ltd. is a clinical-stage
biotechnology company focused on developing a novel therapeutic
platform to address chronic and hard-to-heal wounds, such as DFUs
and VLUs. The Company's novel approach is to treat and close
chronic and other hard-to-heal wounds by injecting the human body's
own wound healing and regenerative components directly into the
wound itself. For more information, please visit
www.Macrocure.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, Section 21E of the US Securities Exchange Act of 1934, as
amended, and the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts, such as
statements regarding assumptions and results related to financial
results forecasts, commercial results, clinical trials and
regulatory authorizations. Forward-looking statements are based on
Macrocure's current knowledge and its present beliefs and
expectations regarding possible future events and are subject to
risks, uncertainties and assumptions. Actual results and the timing
of events could differ materially from those anticipated in these
forward-looking statements as a result of several factors
including, but not limited to, unexpected results of clinical
trials, delays or denial in regulatory approval process or
additional competition in the market. The forward-looking
statements made herein speak only as of the date of this release
and Macrocure undertakes no obligation to update publicly such
forward-looking statements to reflect subsequent events or
circumstances, except as otherwise required by law.
CONTACT: Francesca DeMartino
Investor Relations & Corporate Communications
+1 (310) 739-6476
francesca@macrocure.com
MACROCURE LTD. (NASDAQ:MCUR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
MACROCURE LTD. (NASDAQ:MCUR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024